U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

KAI 1678 is a first-in-class, isoenzyme selective, a small peptide inhibitor of protein kinase C epsilon. It was in development for the treatment of neuropathic and postoperative pain. However, KAI-1678 treatment results were negative.

Originator

Approval Year

Unknown
149124
PubMed

PubMed

TitleDatePubMed
A single-center, randomized, double-blind, active, and placebo-controlled study of KAI-1678, a novel PKC-epsilon inhibitor, in the treatment of acute postoperative orthopedic pain.
2013-06
The safety and efficacy of KAI-1678- an inhibitor of epsilon protein kinase C (εPKC)-versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design.
2013-04
PKC delta and epsilon in drug targeting and therapeutics.
2009
Name Type Language
KP-1678
Preferred Name English
KAI-1678
Common Name English
L-ARGININAMIDE, N-ACETYL-L-.ALPHA.-GLUTAMYL-L-ALANYL-L-VALYL-L-SERYL-L-LEUCYL-L-LYSYL-L-PROLYL-L-THREONYLGLYCYLGLYCYL-L-TYROSYLGLYCYL-L-ARGINYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-ARGINYL-L-GLUTAMINYL-L-ARGINYL-L-ARGINYL-
Systematic Name English
Code System Code Type Description
PUBCHEM
124037376
Created by admin on Mon Mar 31 23:05:57 GMT 2025 , Edited by admin on Mon Mar 31 23:05:57 GMT 2025
PRIMARY
CAS
1253964-58-7
Created by admin on Mon Mar 31 23:05:57 GMT 2025 , Edited by admin on Mon Mar 31 23:05:57 GMT 2025
NO STRUCTURE GIVEN
CLINICAL_TRIALS.GOV
KAI-1678
Created by admin on Mon Mar 31 23:05:57 GMT 2025 , Edited by admin on Mon Mar 31 23:05:57 GMT 2025
PRIMARY Official Title: A Double-Blind, Randomized, Placebo- and Active-Comparator-Controlled, Single-Dose Study to Assess the Efficacy of KAI-1678 Administered by Subcutaneous Infusion in Subjects With Postherpetic Neuralgia, Purpose: The purpose of this study is to determine whether KAI-1678 is effective in the treatment of postherpetic neuralgia pain, Primary Outcome Measures: The effect of KAI-1678 on mean change from baseline in pain intensity at 6 hours (PID 6). (Time Frame: Day 1) (Designated as safety issue: No) Measurements are made using a qualified pain scale and the change from basline is calculated at 6 hours.
CAS
1041004-14-1
Created by admin on Mon Mar 31 23:05:57 GMT 2025 , Edited by admin on Mon Mar 31 23:05:57 GMT 2025
PRIMARY
FDA UNII
32P8I5VL5A
Created by admin on Mon Mar 31 23:05:57 GMT 2025 , Edited by admin on Mon Mar 31 23:05:57 GMT 2025
PRIMARY
ACTIVE MOIETY
KAI-1678
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966